Veracyte
Veracyte
VCYT
NASDAQ
30.14
USD
-0.95%
About
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder).
Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services.
In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 631.4K |
| Three Month Average Volume | 19.5M |
| High Low | |
| Fifty-Two Week High | 33.33 USD |
| Fifty-Two Week Low | 18.61 USD |
| Fifty-Two Week High Date | 16 Aug 2024 |
| Fifty-Two Week Low Date | 18 Apr 2024 |
| Price and Volume | |
| Current Price | 31.55 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 38.26% |
| Thirteen Week Relative Price Change | 42.06% |
| Twenty-Six Week Relative Price Change | 19.56% |
| Fifty-Two Week Relative Price Change | -4.63% |
| Year-to-Date Relative Price Change | -3.15% |
| Price Change | |
| One Day Price Change | -1.22% |
| Thirteen Week Price Change | 52.05% |
| Twenty-Six Week Price Change | 31.46% |
| Five Day Price Change | -1.41% |
| Fifty-Two Week Price Change | 19.51% |
| Year-to-Date Price Change | 14.69% |
| Month-to-Date Price Change | 31.46% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 14.25108 USD |
| Book Value Per Share (Most Recent Quarter) | 14.75722 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.44675 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.49063 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 0.33654 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 4.97011 USD |
| Revenue Per Share (Trailing Twelve Months) | 5.36636 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.02422 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.74441 USD |
| Normalized (Last Fiscal Year) | -0.41266 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.02422 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.7438 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.02422 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.74441 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.95441 USD |
| Cash Per Share (Most Recent Quarter) | 3.07407 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.65007 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.3902 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.53893 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2 |
| Cash Flow Revenue (Trailing Twelve Months) | 10 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -13.71% |
| Pretax Margin (Last Fiscal Year) | -21.22% |
| Pretax Margin (5 Year) | -21.72% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 68.73% |
| Gross Margin (Trailing Twelve Months) | 68.73% |
| Gross Margin (5 Year) | 67.10% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -23.76% |
| Operating Margin (Trailing Twelve Months) | -16.84% |
| Operating Margin (5 Year) | -23.26% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -20.61% |
| Net Profit Margin (Trailing Twelve Months) | -13.52% |
| Net Profit Margin (5 Year) | -20.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 48.83% |
| Tangible Book Value (5 Year) | 30.51% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 26.69% |
| Revenue Growth (3 Year) | 31.45% |
| Revenue Change (Trailing Twelve Months) | 21.59% |
| Revenue Per Share Growth | 14.87% |
| Revenue Growth (5 Year) | 45.39% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 39.67% |
| Total Debt (5 Year) | -66.93% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 164.10% |
| EPS Change (Trailing Twelve Months) | -84.59% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 10 |
| Price to Tangible Book (Most Recent Quarter) | 9 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 71 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 60 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -235,815,000 |
| Net Debt (Last Fiscal Year) | -216,354,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 6 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 4 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 34.3M |
| Free Cash Flow (Trailing Twelve Months) | 40.1M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -6.55% |
| Return on Assets (Trailing Twelve Months) | -4.51% |
| Return on Assets (5 Year) | -6.33% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -7.02% |
| Return on Equity (Trailing Twelve Months) | -4.88% |
| Return on Equity (5 Year) | -6.89% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -6.93% |
| Return on Investment (Trailing Twelve Months) | -4.77% |
| Return on Investment (5 Year) | -6.69% |